Opinion on Biotech in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: Piramed acquisition strengthens its oncology and I&I portfolio

Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.

Published By Datamonitor
15 Apr 2008
CommentWire
CommentWire

Eli Lilly: completes SGX acquisition

Eli Lilly has completed its purchase of US biotechnology company SGX Pharmaceuticals for $64m. The acquisition is expected to compliment Lilly's pursuit of innovative R&D programs, and represents a further investment by a leading pharmaceutical player in the promising US biotechnology industry.

Published By Datamonitor
21 Aug 2008
Expert View
Expert View

Genentech/Merck Serono: is this the end of the line for Raptiva?

Raptiva's safety profile continues to face US and EU regulatory agency scrutiny, which Datamonitor believes will have significant ramifications for the drug's use in psoriasis and any future employment in transplantation. With fresh concern over the safety of Genentech's drug, alternative therapies are likely to impact upon Raptiva's commercial potential.

Published By Datamonitor
23 Feb 2009
CommentWire
CommentWire

Genentech/Roche/Chugai: Herceptin shows activity in gastric cancer

Already a widely used therapy in HER-2-positive breast cancer patients, Herceptin now has the potential to establish itself in the equivalent gastric cancer subset following positive survival results in a pivotal trial. However, with other top-selling targeted therapy drugs also in late-stage development for the same indication, competition is on the horizon.

Published By Datamonitor
18 Mar 2009
CommentWire
CommentWire

Jazz Pharmaceuticals/UCB: fibromyalgia beckons for narcolepsy drug

New positive top-line results from a second Phase III clinical trial of sodium oxybate in fibromyalgia show that the drug is on track for FDA approval. As such, the treatment is set to enter the market as the fourth drug to be approved for fibromyalgia in the US. Despite impressive efficacy data, however, prescriptions are likely to be limited by accessibility, price and convenience.

Published By Datamonitor
26 Jun 2009
CommentWire
CommentWire

Biogen Idec: shifting its multiple sclerosis pipeline

Biogen's MS pipeline has been in the spotlight this week due to negative Phase II data for CDP323 and the company's announcement of an agreement to develop and commercialize Fampridine SR outside the US. While the CDP323 results have led to the drug being shelved, Biogen's continuing activity in broadening its strong MS pipeline shows its resolve in maintaining its leading position in this market.

Published By Datamonitor
02 Jul 2009
Expert View
Expert View

ICAD 2009: beta-amyloid remains center stage at Alzheimer's disease conference

In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.

Published By Datamonitor
22 Jul 2009
CommentWire
CommentWire

ICAD 2009: tau emerges as a viable target for immunotherapy in Alzheimer's

Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.

Published By Datamonitor
22 Jul 2009
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Amgen: Vectibix disappoints in colorectal cancer but hope remains

Amgen's Vectibix has failed to meet a secondary endpoint of overall survival in patients with KRAS wild-type metastatic colorectal cancer. This is a setback as initial positive results for the drug had suggested a strong positioning against Erbitux in the first-line. However, Vectibix did show a trend towards an improvement in survival, and Amgen may now consider further trials on this basis.

Published By Datamonitor
06 Nov 2009

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.